About Belhaven Biopharma

Scott Lyman is the CEO and a Co-Founder of Belhaven Biopharma and serves as Chairman of the Board. Prior to founding Belhaven, he was the Chief Business Officer of Grid Therapeutics, a spinout from Duke University. Scott has previously held leadership roles at GSK, BioCryst, and Salix. His prior experience includes developing spray dried powders, leading drug development teams, participating in FDA filings, and the licensing of multiple products. In these roles, Scott contributed to the approvals of new Enbrel dosage forms, epilepsy medicine Ezogabine, antibiotic Xifaxan, and HIV medicine Tivicay.

Mr. Lyman holds a BS in Chemical Engineering from Iowa State University, a MS in Chemical Engineering from the University of Colorado at Boulder, and an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.

Dave Neal is the CFO and a Co-Founder of Belhaven Biopharma and serves as a Board Member.  Mr. Neal is a leading expert on the intersection of startups, law, and finance.  As a result of his more than two decades as a founder, C-level team member and financier of early-stage companies, he has amassed broad experience in all sectors of the startup landscape. He has managed over $300 million in financing during his career.  In addition to his corporate roles, Dave has been a Professor of Entrepreneurship at the Kenan-Flagler Business School at UNC for more than twenty years and served for five years as an Adjunct Professor of Law at the UNC School of Law.

Mr. Neal holds a BS and a JD from the University of North Carolina at Chapel Hill, and an MBA from Stanford University.

Dr. Eric S. Edwards is currently the co-founder and CEO of Phlow Corporation, a leading impact-driven pharmaceutical company focused on securing the supply chain for critical essential medicines and their ingredients in America.  Previously, Dr. Edwards was the co-founder of Kaléo, Inc., a pharmaceutical company in Richmond, VA developing novel medicines for the treatment of chronic and acute-care diseases. He is co-inventor of several currently marketed products, including AUVI-Q, an epinephrine Auto-injector for the treatment of allergic emergencies (anaphylaxis) as well as the Naloxone Auto-injector (Rapid Opioid Countermeasure System) currently being deployed by the DoD in case of an opioid-related attack on the homeland or abroad as a part of the warfighter’s medical arsenal.

While at Kaleo, Dr. Edwards served as an expert presenter on the FDA Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee for Naloxone in the Community Setting. He has authored numerous publications in the allergy and opioid use disorder space and has been a keynote speaker at numerous conferences on the topics of epinephrine for anaphylaxis, food allergy management, therapeutics for allergic disease, and naloxone for opioid-related emergencies in the community setting. Dr. Edwards has been active on several committees and boards, including being appointed by the Governor to the Board of the Virginia Biotechnology Research Park Authority/ Activation Capital and serving as a mentor and Board member for Lighthouse Labs, a nationally recognized, Top 25 Accelerator. He is also on the founding Board of the Food Allergy Science Initiative (FASI) working with world-class researchers to find a cure and develop treatments for food allergies. Dr. Edwards graduated from Virginia Commonwealth University’s prestigious guaranteed admission program. While at VCU/MCV, he received a B.S. in Biology, his Ph.D. in the Pharmaceutical Sciences, and M.D. degrees.

Wes Wheeler most recently was the President of Global Healthcare, UPS’ first vertical business unit in the company and is specifically focused on pharmaceuticals, medical devices, wholesalers, retail distributors and customers which store or move regulated healthcare products.  Prior to taking this role, Wes was the Chief Executive Officer of Marken, a leading global supply chain service provider to the clinical supply chain industry serving all the leading pharmaceutical sponsors, central laboratories, and contract research organizations in the world. Wes was recruited in 2011 to transform Marken which has grown to more than 50 locations in 27 countries throughout the world. As CEO, he transformed Marken from a single product courier company to the full-service company it is today and was behind his Board’s decision to sell the company in 2016 to UPS in a competitive process. Wes joined the pharmaceutical industry in 1989 with Glaxo (now GlaxoSmithKline) and worked for 12 years, leaving the company in 2003 as Senior Vice President, Global Manufacturing & Supply. While at GSK, Wes was responsible for the manufacturing merger of Glaxo Welcome and SmithKline Beecham. He has since served as CEO / President at four different companies, including Patheon, Valeant and DSM Pharmaceuticals. Prior to joining GSK in 1989, he worked for 12 years as a project engineer for Exxon (now ExxonMobil).

During his 40-year professional career, Wes has been involved in every key functional area in pharmaceuticals, including manufacturing, drug development, supply chain logistics, marketing, and engineering. His combination of deep operational experience and many diverse roles as a leader in many different cultures has provided Wes with a unique range of skills required to transform and grow companies. Wes holds a BS degree in Mechanical Engineering from Worcester Polytechnic Institute and an MBA with an emphasis in Finance.

Derek M. Winstanly, MBChB currently serves as Board Chair of Renovion, a Biophamaceutical Company based out of Durham, NC and Board Member of Huya, a Biophamaceutical Company based out of San Diego, CA. He previously served as the Executive Vice President, Chief Customer and Governance Officer of Quintiles Transnational, November 2011- 2015.  In addition, his responsibilities included Government Affairs, Head of Compliance, Office of Chief Medical Officer and Chair of the Asia Pacific Regional Board. Dr. Winstanly joined Quintiles in 1999 as President of Quintiles Japan and was responsible for the implementation of the Asia Pacific Contract Pharmaceutical Organization, including Pre-clinical, Clinical, Commercial, Academy, and Informatics divisions.  In 2002, he became Chairman of Quintiles Japan and Regional Director for the Asia-Pacific Region. In June 2005, he became the Executive Vice President, Strategic Business Partnerships and Chief Customer Officer. He also has a special interest in patient empowerment and social media and their impact on clinical development.  Prior to joining Quintiles, Dr. Winstanly worked for Glaxo Wellcome, plc, now GlaxoSmithKline, for 15 years. Dr. Winstanly first joined Glaxo South Africa, now Glaxo-SmithKline South Africa, as Medical Director in charge of Clinical Development, Regulatory and Medical Affairs. After being named and serving as Chief Executive Officer of the South African company, Dr. Winstanly moved to the U.K. to accept the position of Director, Migraine & New Therapy areas, where he was responsible for the International Commercial development of all products in these disease areas. Following the merger of Glaxo, Inc. and Burroughs, Wellcome & Co., he was appointed President of Nippon Wellcome, now Glaxo-SmithKline K.K., in Japan. Dr. Winstanly qualified as a Medical Doctor MBChB at the University of Pretoria and is registered as a Medical Practitioner in both the U.K. and South Africa.  In addition, Dr. Winstanly also flew as a pilot with the South African  Airforce and completed a certificate course in Aviation and Space Medicine both in Farnborough, UK and the Institute of Aviation Medicine in South Africa.